Dr. Subudhi on Future Directions With Immunotherapy in Prostate Cancer
Sumit K. Subudhi, MD, PhD, discusses future directions with immunotherapy in prostate cancer.
Sumit K. Subudhi, MD, PhD, discusses future directions with immunotherapy in prostate cancer.
UW Health experts advocate for more women in leadership positions and discuss the need to cultivate diversity to reduce disparities in cancer care.
Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.
Ronan J. Kelly, MD, MBA, discusses the significance of the FDA approval of trastuzumab deruxtecan for pretreated, advanced HER2-positive solid tumors.
PURPOSE Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)–directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non–small-cell lung…
In a recent study, researchers at Huntsman Cancer Institute found a trend in families with male infertility: an increased risk of certain cancers.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The European Medicines Agency has validated an application for nivolumab plus ipilimumab for frontline MSI-H/dMMR metastatic colorectal cancer.
Uproleselan plus chemotherapy did not achieve a statistically significant improvement in OS vs chemotherapy alone in patients with relapsed/refractory AML.
The European Medicines Agency has validated an application for nivolumab plus ipilimumab for frontline MSI-H/dMMR metastatic colorectal cancer.
Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.